Richard M. Elledge, M.D.

Medical Director, Breast Care Center
Associate Professor of Medicine, Baylor College of Medicine

Richard M. Elledge, M.D.Phone: 713-798-1999
Fax: 713-798-8884
Email: relledge@breastcenter.tmc.edu


Publications

Education:
Postgraduate:
1989-1992 - Medical Oncology Fellowship, University of Texas Health Science Center, San Antonio, Texas
1982-1984 - Residency, Methodist Hospital of Dallas, Dallas, Texas
1981-1982 - Internal Medicine Internship, Methodist Hospital of Dallas, Dallas, Texas
Undergraduate:
1981 - University of Texas at Houston Medical School, Houston, Texas (M.D.)
1977 - University of Texas at Austin, Austin, Texas
B.A. in Zoology with honors

Licensure and Certificates:
1993 - American Board of Internal Medicine - Medical Oncology
1984 - Texas State Board of Medical Examiners
1984 - American Board of Internal Medicine - Internal Medicine

Honors and Awards:
1977 - Phi Beta Kappa
1991 - Texas Division of the American Cancer Society Oncology Fellowship Award
1993 - Career Development, Specialized Program for Research Excellence, Breast Cancer
1995 - Fellow, American College of Physicians
1995 - Best Internal Medicine Board Review Course Faculty in the Area of Oncology, ACP Board Review
1996 - Nominated, Presidential Teaching Award
1999 - Nominated, 1999 Gender Equity Award for Clinical Medical Education

Professional Associations and Affiliations:
Editorial Boards:
2000-present - Breast Diseases: A Yearbook Quarterly

Review Panels:
1992-2000 - Breast Cancer Research and Treatment
1993-2000 - Cancer
1994-2000 - Lancet, Journal of the National Cancer Institute, Cancer Research, European Journal of Cancer, Clinical Cancer Research, International Journal of Cancer, Journal of Clinical Oncology

Professional Societies (Elected):
1993 - American Association for Cancer Research
1993 - Southwest Oncology Group
1994 - American Society of Clinical Oncology
1995 - Fellow, American College of Physicians
1999 - National Surgical Breast and Bowel Project

Advisory Boards and Study Sections:
1993 - American Cancer Society Continuing Education Lectures
1995 - Site Visitor, Surgical Oncology Fellowship, University of Miami
1996 - Arimidex Advisory Board, San Antonio, Texas
1996 - Faslodex Protocol Development Board, San Antonio, Texas
1996 - Letrozole Adjuvant Program Advisory Board, Philadelphia, Pennsylvania
1996 - Femora Consultant Panel, Philadelphia, Pennsylvania
1997 - Safety Consultancy Meeting on Long Term Bone and Cardiovascular Side Effects with the Aromatase Inhibitor Letrozole, Trenton, New Jersey
1997 - Herceptin Advisory Board, Dallas, Texas
1997 - Idoxifene Advisory Board, Dallas Texas
1998 - Cox II Advisory Board, Philadelphia, Pennsylvania
1998 - Depocyte Advisory Board, Los Angeles, California
1998 - ERA/923 Consultants Meeting, Philadelphia, Pennsylvania
1998 - Letrozole Manuscript Meeting, Trenton, New Jersey
1998 - Aromatase Inhibitor Round Table, Orlando, Florida
1998 - Herceptin Advisory Board, Orlando Florida
1999 - Manuscript Committee, Letrozole Trials, Trenton, New Jersey
1999 - Herceptin Advisory Board, Cancun, Mexico
2000 - Faslodex Consultant Meeting, Edmonton, Alberta, Canada
2000 - Third Annual Opinion Leader Roundtable "Targeted Therapies in the Treatment of Breast Cancer," Kailua-Kona, Hawaii
2000 - Streams of Excellence Site Visit for the Canadian Breast Cancer Research Initiative (National Cancer Institute of Canada) Toronto, Canada

Committees:
1993-1998 - Medical Records, Methodist Hospital
1994 - Medicine Executive Committee, Methodist Hospital
1995 - Fellowship Curriculum Review Committee
1992-1999 - Medicine Residency Admissions
1995-1999 - Medical Student Admissions
1995-1999 - General Clinical Research Center Advisory Committee
1995-1999 - VA Research and Development Committee
1999-present - NSABP Breast Committee
1999-present - Breast Center EMR Steering Committee
1999-present - Strategic Planning Implementation/Clinical Research Infrastructure Taskforce Committee
2000-present - Cancer Committee of the Medical Staff for 2000, The Methodist Hospital
2000-present - Medical Staff Quality Management Subcommittee, The Methodist Hospital

Brief Description of Research:
Biomarkers as surrogate endpoints in a pilot breast cancer chemoprevention trial using tamoxifen. A multi-center, randomized, double-blind study of Idoxifene 40 mg/day versus Tamoxifen 20 mg/day as first-line hormonal therapy of locally advanced or metastatic breast cancer in postmenopausal women. A multicenter phase III randomized, controlled study of Theratope vaccine for metastatic breast cancer. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. Biologic factors predicting response to Tamoxifen in Patients with ER-positive metastatic breast cancer, SWOG 9319 Evolutionary changes of molecular markers in response to neoadjuvant doxorubicin for locally advanced breast cancer.